 |
PDBsum entry 2gm1
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
Bioorg Med Chem Lett
16:3937-3942
(2006)
|
|
PubMed id:
|
|
|
|
|
| |
|
Synthesis and SAR of pyrrolotriazine-4-one based Eg5 inhibitors.
|
|
K.S.Kim,
S.Lu,
L.A.Cornelius,
L.J.Lombardo,
R.M.Borzilleri,
G.M.Schroeder,
C.Sheng,
G.Rovnyak,
D.Crews,
R.J.Schmidt,
D.K.Williams,
R.S.Bhide,
S.C.Traeger,
P.A.McDonnell,
L.Mueller,
S.Sheriff,
J.A.Newitt,
A.T.Pudzianowski,
Z.Yang,
R.Wild,
F.Y.Lee,
R.Batorsky,
J.S.Ryder,
M.Ortega-Nanos,
H.Shen,
M.Gottardis,
D.L.Roussell.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Synthesis and SAR of substituted pyrrolotriazine-4-one analogues as Eg5
inhibitors are described. Many of these analogues displayed potent inhibitory
activities in the Eg5 ATPase and A2780 cell proliferation assays. In addition,
pyrrolotriazine-4-one analogue 26 demonstrated in vivo efficacy in an iv P388
murine leukemia model. Both NMR and X-ray crystallographic studies revealed that
these analogues bind to an allosteric site on the Eg5 protein.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
S.K.Talapatra,
A.W.Schüttelkopf,
and
F.Kozielski
(2012).
The structure of the ternary Eg5-ADP-ispinesib complex.
|
| |
Acta Crystallogr D Biol Crystallogr,
68,
1311-1319.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
C.Jiang,
Q.You,
F.Liu,
W.Wu,
Q.Guo,
J.Chern,
L.Yang,
and
M.Chen
(2009).
Design, synthesis and evaluation of tetrahydroisoquinolines as new kinesin spindle protein inhibitors.
|
| |
Chem Pharm Bull (Tokyo),
57,
567-571.
|
 |
|
|
|
|
 |
X.Teng,
H.Keys,
J.Yuan,
A.Degterev,
and
G.D.Cuny
(2008).
Structure-activity relationship and liver microsome stability studies of pyrrole necroptosis inhibitors.
|
| |
Bioorg Med Chem Lett,
18,
3219-3223.
|
 |
|
|
|
|
 |
C.Jiang,
Y.Chen,
X.Wang,
and
Q.You
(2007).
Docking studies on kinesin spindle protein inhibitors: an important cooperative 'minor binding pocket' which increases the binding affinity significantly.
|
| |
J Mol Model,
13,
987-992.
|
 |
|
|
|
|
 |
I.Garcia-Saez,
S.DeBonis,
R.Lopez,
F.Trucco,
B.Rousseau,
P.Thuéry,
and
F.Kozielski
(2007).
Structure of human Eg5 in complex with a new monastrol-based inhibitor bound in the R configuration.
|
| |
J Biol Chem,
282,
9740-9747.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
T.C.Krzysiak,
and
S.P.Gilbert
(2006).
Dimeric Eg5 maintains processivity through alternating-site catalysis with rate-limiting ATP hydrolysis.
|
| |
J Biol Chem,
281,
39444-39454.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
code is
shown on the right.
|
');
}
}
 |